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Abstract
We report here the development of fluorescence-guided surgery of liver metastasis. HT29
human colon cancer cells expressing green fluorescent protein (GFP) were initially injected
in the spleen of nude mice. Three weeks later, established liver metastases were harvested
and implanted on the left lobe of the liver in other nude mice in order to make an orthotopic
liver metastasis model. Fourteen mice with a single liver metastasis were randomized into
bright-light surgery (BLS) or fluorescence-guided surgery (FGS) groups. Seven mice were
treated with BLS, seven were treated with FGS. Three weeks after implantation, the left
lobe of the liver with a single metastasis was exposed through a median abdominal incision.
BLS was performed under white light. FGS was performed using a hand-held portable fluo-
rescence imaging system (Dino-Lite). Post-surgical residual tumor fluorescence was visual-
ized with the OV100 Small Animal Imaging System. Residual tumor fluorescence after BLS
was clearly visualized at high magnification with the OV100. In contrast, residual tumor fluo-
rescence after FGS was not detected even at high magnification with the OV100. These
results demonstrate the feasibility of FGS for liver metastasis.
Introduction
The ability of the surgeon to accurately visualize tumor margins is essential at the time of surgery
and is of particular importance for resection of metastatic disease, especially in the liver [1].
A variety of labeling compounds have been used for fluorescence-guided surgery in the
clinic. Sentinel lymph nodes in breast cancer patients were labeled by a near-infrared (NIR)
fluorescing dye indocyanine [2]. However, indocyanine does not specifically label tumor cells.
The metabolite 5-aminolevulinic acid, a precursor of hemoglobin, labels porphyrins in malig-
nant glioma for FGS [3], which significantly improved outcome.
Folate was coupled to fluorescein isothiocyanate (FITC) for targeting folate receptor–α (FR-
α) in ovarian cancers. Under fluorescence-guided surgery, tumor deposits less than 1 mm in
size could be visualized and resected [4].
Monoclonal antibodies directed against cancer antigen 19–9 (CA19-9) or carcino-embry-
onic antigen (CEA) were conjugated to a green fluorophore and delivered intravenously into
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nude mice with orthotopic human pancreatic or colon tumors [5]. The tumors become fluores-
cent and were resected under fluorescence-guidance improved outcome [5–10].
Kishimoto et al. [11] labeled tumors with green fluorescence protein (GFP) using a telomerase-
dependent adenovirus (OBP-401) that expresses the gfp gene only in cancer cells, which, in con-
trast to normal cells, express the telomerase enzyme. The labeled tumors could also be resected
under fluorescence guidance. Tumors that recurred after fluorescence-guided surgery maintained
GFP expression [12]. Since the cancer cells stably express GFP, detection of cancer recurrence and
metastasis is possible with OBP-401 GFP labeling, and is not possible with nongenetic probes.
The present report demonstrates the feasibility of FGS of liver metastasis labeled with GFP
in orthotopic mouse models.
Materials and Methods
Ethics Statement
All animal studies were conducted with an AntiCancer Institutional Animal Care and Use
Committee (IACUC)-protocol specifically approved for this study and in accordance with the
principals and procedures outlined in the National Institute of Health Guide for the Care and
Use of Animals under Assurance Number A3873-1. In order to minimize any suffering of the
animals, anesthesia and analgesics were used for all surgical experiments. Animals were anes-
thetized by intramuscular injection of a 0.02 ml solution of 20 mg/kg ketamine, 15.2 mg/kg
xylazine, and 0.48 mg/kg acepromazine maleate. The response of animals during surgery was
monitored to ensure adequate depth of anesthesia. Ibuprofen (7.5 mg/kg orally in drinking
water every 24 hours for 7 days post-surgery) was used in order to provide analgesia post-oper-
atively in the surgically-treated animals. The animals were observed on a daily basis and
humanely sacrificed by CO2 inhalation when they met the following humane endpoint criteria:
prostration, skin lesions, significant body weight loss, difficulty breathing, epistaxis, rotational
motion and body temperature drop. The use of animals was necessary to develop fluorescence-
guided surgery of liver metastasis. Animals were housed with no more than 5 per cage. Animals
were housed in a barrier facility on a high efficiency particulate arrestance (HEPA)-filtered
rack under standard conditions of 12-hour light/dark cycles. The animals were fed an auto-
claved laboratory rodent diet (S1 ARRIVE Checklist).
Cell Line
The human colon cancer cell line HT-29 [10], obtained from the American Type Culture Collec-
tion (Rockville, MD) was maintained in DMEM (Irvine Scientific, Irvine, CA) supplemented
with heat-inactivated 10% fetal bovine serum (FBS) (Gemini Biologic Products, Calabasas, CA),
2 mM glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin
B (Life Technologies, Inc., Grand Island, NY). The cells were incubated at 37°C in 5% CO2.
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4–6 weeks old, were used in this
study. Mice were kept in a barrier facility under HEPA filtration (as noted above). Mice were
fed with an autoclaved laboratory rodent diet. All mouse surgical procedures and imaging were
performed with the animals anesthetized by subcutaneous injection of the ketamine mixture
described above. All animal studies were conducted with an AntiCancer Institutional Animal
Care and Use Committee (IACUC)-protocol specifically approved for this study and in accor-
dance with the principals and procedures outlined in the National Institute of Health Guide for
the Care and Use of Animals under Assurance Number A3873-1.
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Establishment of GFP-labeled HT29
For GFP gene transfection, 25% confluent HT-29 cells were incubated with a 1:1 mixture of
GFP retroviral supernatants of PT67 packaging cells and RPMI 1640 cell culture medium
(GIBCO Life Technologies, New. York, NY) containing 10% FBS (Gemini Biological Products)
for 72 h. Fresh medium was replenished at this time. Cells were harvested by trypsin-EDTA
72 h after transduction and subcultured at a ratio of 1:15 into medium, which contained
200 μg/ml G418 to select for high GFP expression, since the GFP retrovirus also contained the
neomycin-resistance gene. The level of G418 was increased to 400 μg/ml stepwise. Clones sta-
bly expressing GFP were isolated with cloning cylinders (Bel-Art Products, Pequannock, NJ)
with the use of trypsin-EDTA. The high-GFP-expressing cells were then amplified and trans-
ferred by conventional culture methods. High GFP-expression clones were then isolated in the
absence of G418 for 10 passages to select for stable expression of GFP [13–15].
Initial Establishment of Liver Metastasis
HT-29-GFP cells were harvested by trypsinization and washed twice with serum-free medium.
Cells (5×105 in 50 μl serum-free medium with 50%Matrigel) were injected into the superior
Fig 1. HT29-GFP colon cancer experimental liver metastasis. (A) HT-29-GFP cells (5×105 in 50 μl with 50%Matrigel) were injected into the superior pole
and inferior pole of the spleen (arrows), respectively. (B) Three weeks after injection, liver metastasis was confirmed by laparotomy, which was resected and
cut into 3-mm3 blocks. Each tumor fragment was implanted by surgical orthotopic implantation (SOI) in the left lobe of the liver on other nude mice. (C)
Representative images of liver metastasis established after spleen injection. The large tumor in the liver strongly expressed GFP. (GFP, green fluorescent
protein; BF, bright field)
doi:10.1371/journal.pone.0138752.g001
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and inferior pole of the spleen in mice (Fig 1A). Three week after injection, liver metastasis was
confirmed by laparotomy (Fig 1C).
Surgical orthotopic Implantation (SOI) of Liver Metastasis
Liver metastases were resected and cut into 8 mm3 blocks. A small 6- to 8-mmmidline incision
was made in other nude mice. The left lobe of the liver was exposed through this incision, and
a single tumor fragment (3-mm3) was orthotopically implanted to the left lobe of the liver (Fig
1B). The left lobe of the liver was returned to the abdominal cavity, and the incision was closed
in one layer using 6–0 nylon surgical sutures (Ethilon; Ethicon Inc., NJ, USA).
Bright-Light and Fluorescence-Guided Surgery of Liver Metastases
Four weeks after SOI of HT-29-GFP to the liver, the liver metastasis was exposed and imaged
preoperatively with the OV100 Small Animal Imaging System (Olympus, Tokyo, Japan) [16] at
a magnification of 0.14x. Fourteen mice underwent surgery: Fluorescence-guided surgery
(FGS) in 7 mice and bright-light surgery (BLS) in 7 mice (Fig 2A and 2B). FGS was performed
using the Dino-Lite imaging system (AM4113TGFBWDino-Lite Premier; AnMo Electronics
Corporation, New Taiwan). The surgical resection bed was imaged with the Olympus OV100
at a magnification of 0.14x or 0.56x to detect microscopic residual cancer. Residual tumor area
was analyzed with ImageJ v1.49f (National Institutes of Health). The incision was closed in one
layer using 6–0 nylon surgical sutures.
Fig 2. Schematic diagram of the experimental design. (A) Fourteen mice were randomized into 2 groups; FGS: n = 7, BLS: n = 7. (B) Timeline from
orthotopic implantation. Four weeks after implantation, all mice were treated with FGS or BLS. Twenty-eight days after the surgery, all mice underwent
laparotomy to detect GFP for evaluation of recurrence. After the laparotomy, follow-up examination for survival was continued. (FGS, fluorescence-guided
surgery; BLS, bright-light surgery).
doi:10.1371/journal.pone.0138752.g002
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Imaging of Tumor Progression
To evaluate tumor fluorescence around the resected site in the liver, laparotomy was performed
in all mice at the 28th post-operative day (Fig 2B). Tumor fluorescence was detected with the
OV100 and analyzed with ImageJ.
Tumor histology
Resected fresh tumor samples from either BLS or FGS were fixed in 10% formalin, and then
embedded in paraffin. The tissue sections were deparaffinized in xylene and rehydrated in an
ethanol series. Hematoxylin and eosin (H & E) staining was performed according to standard
protocols. The margin between the tumor and the liver tissue was evaluated with a BHS System
microscope (Olympus).
Statistical Analysis
SPSS statistics version 21.0 was used for all statistical analyses (IBM, New York City, NY,
USA). Residual tumor area is expressed as mean ± SD. Significant differences for continuous
Fig 3. Pre-operative and post-operative images from the orthotopic liver metastasis model treated with BLS. (A)—(C) Upper panels show bright field
images, and lower panels are images of tumor fluorescence obtained with the OV100. At low magnification, residual tumor fluorescence was marginally
detected. (B) However, at high magnification, residual tumor fluorescence was clearly visualized (arrows) (C). Arrowheads show residual tumor fluorescence
inB andC. (D) Resected specimen. Magnifications are indicated above the columns.
doi:10.1371/journal.pone.0138752.g003
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variables were determined using the Mann-Whitney U test. A probability value of P 0.05
was considered statistically significant.
Fig 4. Pre-operative and post-operative images from the orthotopic liver metastasis model treated with FGS. (A)—(C) Upper panels show bright field
images, and lower panels are images of tumor fluorescence obtained with the OV100. Residual tumor fluorescence could not be detected even at high
magnification (C). (D,F,H) Pre-FGS tumor fluorescence was clearly visualized with the Dino-Lite imaging system. (E,G,I) Dino-Lite imaging showed no
evidence of tumor after FGS. (J-K) Dino-Lite settings. (J) After exposing the left lobe of the liver, the mouse was put under the Dino-Lite. (K) Connection
between the Dino-Lite and computer. Tumor fluorescence was imaged on the monitor during FGS. Magnifications are indicated above the columns.
doi:10.1371/journal.pone.0138752.g004
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Results and Discussion
FGS significantly reduces residual liver metastasis
Single liver metastases were clearly detected preoperatively with the OV100 (Figs 3A and 4A). In
the BLS group, residual tumor fluorescence was marginally detected at a magnification of 0.14×.
However, at a magnification of 0.56×, residual cancer was clearly visualized (Fig 3B and 3C). By
contrast, residual tumor fluorescence could not be detected even at a magnification of 0.56× in
the FGS group (Fig 4B and 4C). Tumor fluorescence was also clearly visualized before FGS with
the Dino-Lite at a magnification of 30× (Fig 4D). Dino-Lite imaging showed no evidence of resid-
ual cancer after FGS (Fig 4E). All resected specimens exhibited strong GFP expression (Fig 3D).
Histologically, viable cancer was detected on the resection line in the BLS group, but not in the
FGS group which had clear margins (Fig 5), which is consistent with the fluorescence data.
Fig 5. Histological tumor margin of resected specimen. (A)-(C) H&E staining of resected specimen. (A) In the mouse treated with FGS, viable cancer
tissue (marked by an asterisk) is surrounded by normal liver tissues. (B) High magnification of (A). (C) In the BLS-treated mouse, viable cancer cells are
visible along the resection line. Arrows show residual cancer tissue. Dashed lines separate viable cancer and normal liver tissue. Scale bars: 200 μm.
doi:10.1371/journal.pone.0138752.g005
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Residual tumor area after BLS was significantly larger than after FGS (0.34 ± 0.28 mm2 and
0 mm2, respectively; P = 0.003; Fig 6).
FGS significantly decreases recurrent tumor area
Laparotomy was performed at 28 postoperative day. Recurrent tumor fluorescence was visual-
ized next to the resected site in the liver in the BLS group, but not in the FGS group (Fig 7). In
the FGS group, only autofluorescence was detected.
The FGS procedure for liver metastasis described in the present report had short- and long-
term advantages over BLS in that most if not all of the metastasis was resected by FGS com-
pared to BLS (Figs 3–6), and this advantage was maintained even at 28 days post-surgery,
where recurrence was greatly reduced by FGS compared to BLS (Fig 7). Future studies will
devise curative strategies for FGS of liver metastasis.
Conclusions
The results of present study suggest that FGS has clinical potential of reducing residual cancer
in patients who have liver metastasis resected. Clinical application strategies could include
labeling the liver metastasis with a tumor-specific monoclonal antibody such as anti-carcino-
embryonic antigen (anti-CEA) conjugated to a fluorophore [5–10] or labeled by a telomerase-
dependent cancer-specific adenovirus that contains the GFP gene, OBP-401 [11, 12, 17–19].
Fig 6. Bar graph of residual tumor area after surgery.No residual tumor was detected in the FGS group. Residual tumor area after BLS was relatively
large. Error bar shows SD. **P<0.01.
doi:10.1371/journal.pone.0138752.g006
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The labeled-antibody strategy is probably feasible in the near future. The viral-labeling strategy
will require more safety studies. However, the parent virus of OBP-401, OBP-301, has proven
safe in a clinical trial [20]. However, OBP-401 will also have safety tested in a clinical trial.
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